Tech Meridian ← LIVE FEED
PROMY MERIDIAN RU

FUNDING · STARTUPS · #3733

Isomorphic Labs raises $5B Series C to push AI-designed drug candidates toward clinical trials

Isomorphic Labs, the AI drug-discovery spinout from DeepMind, raised $5 billion in a Series C round co-led by Greenoaks and Sequoia Capital with participation from Andreessen Horowitz and existing backers including GV, CapitalG, Thrive Capital, MGX, Temasek and the UK Sovereign AI Fund. The company says it will use the funding to further develop its AI drug-design engine — built on techniques from DeepMind’s AlphaFold work — and to advance AI-designed candidates that have shown reported positive preclinical results in oncology and immunology toward clinical trials; it has partnerships with Eli Lilly, Novartis and Johnson & Johnson and did not disclose a valuation (Bloomberg earlier reported it sought a $50 billion valuation).

KEY POINTS

  1. Isomorphic Labs, the AI drug-discovery spinout from DeepMind, raised $5 billion in a Series C round co-led by Greenoaks and Sequoia Capital with participation from Andreessen Horowitz and existing backers including GV, CapitalG, Thrive Capital, MGX, Temasek and the UK Sovereign AI Fund.
  2. The company says it will use the funding to further develop its AI drug-design engine — built on techniques from DeepMind’s AlphaFold work — and to advance AI-designed candidates that have shown reported positive preclinical results in oncology and immunology toward clinical trials; it has partnerships with Eli Lilly, Novartis and Johnson & Johnson and did not disclose a valuation (Bloomberg earlier reported it sought a $50 billion valuation).
  3. A $5B round led by top investors signals substantial market confidence in AI-driven drug discovery and could accelerate the translation of computationally designed molecules into clinical testing.
MERIDIAN INTELLIGENCE

DECISION BRIEF

70/100
CONFIDENCE
01

WHAT CHANGED

Isomorphic Labs raised $5 billion in a Series C round (co-led by Greenoaks and Sequoia Capital, with participation from Andreessen Horowitz and existing backers) and says it will use the funding to further develop its AI drug-design engine and push AI-designed candidates that have shown reported positive preclinical results in oncology and immunology toward clinical trials.

02

WHY NOW

A second mega-round within months (following a $2.1B Series B in May) and participation by top venture investors signal large private capital commitment to Isomorphic’s push from computational design toward clinical testing; the company frames the funding as intended to accelerate its Iso/AI drug-design platform and pipeline advancement.

03

WHO IS AFFECTED

Directly named entities: Isomorphic Labs; investors that participated (Greenoaks, Sequoia Capital, Andreessen Horowitz, GV, CapitalG, Thrive Capital, MGX, Temasek, UK Sovereign AI Fund); pharma partners named (Eli Lilly, Novartis, Johnson & Johnson); DeepMind/Alphabet (origin and personnel connections mentioned).

04

CONFIRMED

Explicit source-backed facts - Isomorphic Labs raised $5 billion in a Series C round (sources report the round was co-led by Greenoaks and Sequoia Capital; Andreessen Horowitz and the company’s existing backers participated). (4417, 4422) - The company previously raised $2.1 billion in a Series B in May 2026. (4417, 4422) - Isomorphic builds an AI drug-design engine that the company says builds on DeepMind/AlphaFold work and has described an in-house platform (referred to as IsoDDE). (4417, 4422) - The company states its programs have produced “positive preclinical results” in oncology and immunology. (4417) - Isomorphic has deals/partnerships with Eli Lilly, Novartis, and Johnson & Johnson. (4417, 4422) - The company has no approved drug to date (explicitly stated in one source). (4422) - Company leadership: Demis Hassabis is identified as leading the company in the reporting and is referenced in connection with DeepMind/AlphaFold work and a Nobel Prize. (4417, 4422) - The company did not disclose a valuation in the coverage; Bloomberg was reported by one source to have earlier said the company sought a $50 billion valuation. (4417)

05

UNCERTAIN

Missing or conflicting evidence (explicitly flagged) - Valuation: the company did not disclose a valuation; one source cites an earlier Bloomberg report that the company sought a $50 billion valuation. The valuation is not confirmed in the supplied excerpts. (4417) - Preclinical results: sources quote the company’s statement of “positive preclinical results” in oncology and immunology but provide no details on which candidates, study designs, endpoints, or data are behind that claim. No peer-reviewed data or specific study results are provided in the excerpts. (4417) - Clinical advancement: the company says it will push candidates toward clinical trials, but there is no explicit, corroborated evidence in the excerpts that INDs/clinical trial registrations have been filed or initiated. (4417, 4422) - Leadership and personnel moves: excerpts reference changes in Demis Hassabis’s role and broader DeepMind staffing (one source notes Hassabis left his position as head of DeepMind and moved to a chairman role; another gives a different formulation of timing and title). Details and timing of those role changes and of reported DeepMind team reassignments or departures are inconsistent or under-specified in the excerpts. (4417, 4422) - Technical claims (IsoDDE vs AlphaFold 3): one source reports the company’s claim that IsoDDE “goes beyond AlphaFold 3”; this is a company claim in the excerpt and is not independently substantiated in the supplied text. (4422) - Regulatory and development status: whether any Isomorphic candidate has IND-enabling data accepted by regulators or submitted to regulatory authorities is not stated.

06

WHAT TO WATCH

Concrete observable signals to monitor next - Official company announcements or filings that disclose valuation or financing terms. (4417) - IND submissions or clinical trial registrations (e.g., entries on ClinicalTrials.gov or equivalent regulators) for Isomorphic-designed candidates. (4417, 4422) - Press releases or peer-reviewed publications that disclose preclinical data (study details, endpoints, reproducible results) for the claimed oncology and immunology candidates. (4417) - Regulatory milestones or statements from pharma partners (Eli Lilly, Novartis, Johnson & Johnson) about joint programs or trial starts. (4417, 4422) - Technical publications or detailed disclosures about IsoDDE/AlphaFold-derived models or model performance beyond company claims. (4422) - Further reporting or company statements clarifying leadership changes and DeepMind staff movements referenced in the coverage.

WHY IT MATTERS

A $5B round led by top investors signals substantial market confidence in AI-driven drug discovery and could accelerate the translation of computationally designed molecules into clinical testing.

EVIDENCE MAP

4

Editorial claims linked to specific sources, with support, contradiction and context shown separately.

The Series C was co-led by Greenoaks and Sequoia Capital, with participation from Andreessen Horowitz and existing investors including Alphabet-linked funds.

SUPPORTED

Checked 2026-11-17 · 2 supporting

The company says it will use the funding to further develop its AI drug-design engine and to advance AI-designed candidates toward clinical trials.

SUPPORTED

Checked 2026-11-17 · 2 supporting

Isomorphic Labs reports that its program has yielded positive preclinical results in oncology and immunology.

SUPPORTED

Checked 2026-11-17 · 1 supporting

SOURCES & TIMELINE

2